| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| S J Grcevich, R L Findling, W A Rowane, L Friedman, S C Schul. Risperidone in the treatment of children and adolescents with schizophrenia: a retrospective study. Journal of child and adolescent psychopharmacology. vol 6. issue 4. 1997-08-12. PMID:9231318. |
risperidone appeared to be safe and effective in ameliorating symptoms of schizophrenia in this age group. |
1997-08-12 |
2023-08-12 |
Not clear |
| J L Armenteros, A H Whitaker, M Welikson, D J Stedge, J Gorma. Risperidone in adolescents with schizophrenia: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 36. issue 5. 1997-06-24. PMID:9136505. |
risperidone in adolescents with schizophrenia: an open pilot study. |
1997-06-24 |
2023-08-12 |
Not clear |
| J L Armenteros, A H Whitaker, M Welikson, D J Stedge, J Gorma. Risperidone in adolescents with schizophrenia: an open pilot study. Journal of the American Academy of Child and Adolescent Psychiatry. vol 36. issue 5. 1997-06-24. PMID:9136505. |
to assess critically the short-term efficacy and safety of risperidone in adolescents with schizophrenia. |
1997-06-24 |
2023-08-12 |
Not clear |
| F Son. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. Journal of psychopharmacology (Oxford, England). vol 11. issue 1. 1997-06-19. PMID:9097896. |
risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. |
1997-06-19 |
2023-08-12 |
Not clear |
| F Son. Risperidone in the treatment of schizophrenia: a meta-analysis of randomized controlled trials. Journal of psychopharmacology (Oxford, England). vol 11. issue 1. 1997-06-19. PMID:9097896. |
it was concluded that the short-term efficacy of risperidone is comparable to other neuroleptics in the treatment of schizophrenia. |
1997-06-19 |
2023-08-12 |
Not clear |
| M F Green, B D Marshall, W C Wirshing, D Ames, S R Marder, S McGurk, R S Kern, J Mint. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? The American journal of psychiatry. vol 154. issue 6. 1997-06-18. PMID:9167507. |
does risperidone improve verbal working memory in treatment-resistant schizophrenia? |
1997-06-18 |
2023-08-12 |
Not clear |
| S M Aronso. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone. Clinical therapeutics. vol 19. issue 1. 1997-06-06. PMID:9083716. |
thus the use of risperidone, a more effective but more expensive antipsychotic medication, can decrease the total cost of care for patients with chronic schizophrenia by decreasing the need for hospitalization. |
1997-06-06 |
2023-08-12 |
Not clear |
| N A Kek. Impact of newer antipsychotics on outcomes in schizophrenia. Clinical therapeutics. vol 19. issue 1. 1997-06-06. PMID:9083717. |
newer antipsychotics, such as risperidone, produce better cognitive function in patients with schizophrenia than do conventional neuroleptics, which implies that the indirect costs of the illness will be less in patients treated with risperidone. |
1997-06-06 |
2023-08-12 |
Not clear |
| N A Kek. Impact of newer antipsychotics on outcomes in schizophrenia. Clinical therapeutics. vol 19. issue 1. 1997-06-06. PMID:9083717. |
a robust decision-analytic model of schizophrenia suggests that the overall cost of treating a patient with risperidone is $11,772.00 per year compared with $13,622.00 per year for haloperidol and that the cost per response is even more favorable toward risperidone--$14,599.00 versus $23,040.00. |
1997-06-06 |
2023-08-12 |
Not clear |
| D D Cung, G L Stimme. Reemergence of positive symptoms after initial response to risperidone. Pharmacotherapy. vol 17. issue 2. 1997-05-27. PMID:9085334. |
risperidone was effective in successfully treating a patient's negative symptoms of schizophrenia as well as reducing adverse effects from typical antipsychotic drugs. |
1997-05-27 |
2023-08-12 |
Not clear |
| D D Cung, G L Stimme. Reemergence of positive symptoms after initial response to risperidone. Pharmacotherapy. vol 17. issue 2. 1997-05-27. PMID:9085334. |
reemergence of psychotic symptoms after initial response might be explained by inadequate dosage, by the natural course of the patient's schizophrenia independent of drug therapy, or by the possibility that, for this patient, risperidone was less effective than chlorpromazine for the positive symptom of auditory hallucinations. |
1997-05-27 |
2023-08-12 |
Not clear |
| J A Matte. Risperidone: how good is the evidence for efficacy? Schizophrenia bulletin. vol 23. issue 1. 1997-05-21. PMID:9050121. |
it is as yet unclear whether risperidone is as effective as standard neuroleptics for positive schizophrenia symptoms in neuroleptic-responsive patients. |
1997-05-21 |
2023-08-12 |
Not clear |
| A Rossi, F Mancini, P Stratta, P Mattei, R Gismondi, F Pozzi, M Casacchi. Risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. Acta psychiatrica Scandinavica. vol 95. issue 1. 1997-05-20. PMID:9051159. |
risperidone, negative symptoms and cognitive deficit in schizophrenia: an open study. |
1997-05-20 |
2023-08-12 |
Not clear |
| R C Smith, R P Kadewar. Neurological soft signs and response to risperidone in chronic schizophrenia. Biological psychiatry. vol 40. issue 10. 1997-05-13. PMID:8915566. |
neurological soft signs and response to risperidone in chronic schizophrenia. |
1997-05-13 |
2023-08-12 |
Not clear |
| D J Still, P G Dorson, M L Crismon, C Pousso. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatric services (Washington, D.C.). vol 47. issue 12. 1997-04-23. PMID:9117479. |
effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. |
1997-04-23 |
2023-08-12 |
Not clear |
| D J Still, P G Dorson, M L Crismon, C Pousso. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatric services (Washington, D.C.). vol 47. issue 12. 1997-04-23. PMID:9117479. |
a prospective, open-label study in a 400-bed state psychiatric hospital evaluated change in therapeutic response among ten patients with treatment-resistant schizophrenia who were switched from clozapine to risperidone. |
1997-04-23 |
2023-08-12 |
Not clear |
| D J Still, P G Dorson, M L Crismon, C Pousso. Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatric services (Washington, D.C.). vol 47. issue 12. 1997-04-23. PMID:9117479. |
the findings do not support replacing clozapine with risperidone for patients with treatment-resistant schizophrenia. |
1997-04-23 |
2023-08-12 |
Not clear |
| G E Davis, W E Lowell, G L Davi. Measuring quality of care in a psychiatric hospital using artificial neural networks. American journal of medical quality : the official journal of the American College of Medical Quality. vol 12. issue 1. 1997-04-18. PMID:9116530. |
the study took place during hospital downsizing (political change), a consent decree (policy change), new administrative and medical personnel (staffing change), and the introduction of clozapine and risperidone for schizophrenia (therapeutic change). |
1997-04-18 |
2023-08-12 |
Not clear |
| I R de Oliveira, A M Miranda-Scippa, E P de Sena, E L Pereira, M G Ribeiro, E de Castro-e-Silva, J Bacaltchu. Risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. Journal of clinical pharmacy and therapeutics. vol 21. issue 5. 1997-04-18. PMID:9119918. |
risperidone versus haloperidol in the treatment of schizophrenia: a meta-analysis comparing their efficacy and safety. |
1997-04-18 |
2023-08-12 |
Not clear |
| J K Patel, C Salzman, A I Green, M T Tsuan. Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. The American journal of psychiatry. vol 154. issue 4. 1997-04-16. PMID:9090343. |
chronic schizophrenia: response to clozapine, risperidone, and paroxetine. |
1997-04-16 |
2023-08-12 |
Not clear |